Mobile

Study in patients with primary Sjögren’s syndrome with the aim to assess safety, tolerability, pharmacokinetics (way the body absorbs, distributes, and gets rid of the drug) and preliminary efficacy o...

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-004808-19

Study in patients with primary Sjögren’s syndrome with the aim to assess safety, tolerability, pharmacokinetics (way the body absorbs, distributes, and gets rid of the drug) and preliminary efficacy of CFZ533

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To assess the safety and tolerability of multiple intravenous infusion of CFZ533 in patients with primary Sjögren’s syndrome as measured by adverse events (AEs) • To compare the effect of multiple intravenous infusion of CFZ533 versus placebo on the clinical disease activity of primary Sjögren’s syndrome patients as measured by the change of an EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) after 12 weeks treatment.

Critère d'inclusion

  • Primary Sjögren’s syndrome

Liens